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S U M M A R Y
Objectives: The acquisition of carbapenemases by Acinetobacter baumannii is reported increasingly
worldwide, but data from Lebanon are limited. The aims of this study were to evaluate the prevalence of
imipenem-resistant A. baumannii in Lebanon, identify resistance determinants, and detect clonal
relatedness.
Methods: Imipenem-resistant A. baumannii were collected from nine Lebanese hospitals during
2012. Antimicrobial susceptibility, the cloxacillin effect, and ethylenediaminetetraacetic acid (EDTA)
synergy were determined. Genes encoding carbapenemases and insertion sequence ISAba1 were
screened via PCR sequencing. ISAba1 position relative to genes encoding Acinetobacter-derived
cephalosporinases (ADCs) and OXA-23 was studied by PCR mapping. Clonal linkage was examined by
enterobacterial repetitive intergenic consensus PCR (ERIC-PCR).
Results: Out of 724 A. baumannii isolated in 2012, 638 (88%) were imipenem-resistant. Of these,
142 were analyzed. Clavulanic acid–imipenem synergy suggested carbapenem-hydrolyzing extended-
spectrum b-lactamase. A positive cloxacillin test indicated ADCs, while EDTA detection strips were
negative. Genotyping indicated that 90% of isolates co-harbored blaOXA-23 and blaGES-11. The remaining
strains had blaOXA-23, blaOXA-24, blaGES-11, or blaOXA-24 with blaGES-11. ISAba1 was located upstream of
blaADC and blaOXA-23 in 97% and 100% of isolates, respectively. ERIC-PCR ﬁngerprinting revealed
18 pulsotypes spread via horizontal gene transfer and clonal dissemination.
Conclusion: This survey established baseline evidence of OXA-23 and GES-11-producing A. baumannii in
Lebanon, indicating the need for further surveillance.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Acinetobacter baumannii is a Gram-negative, non-fermenting
opportunistic pathogen that is frequently associated with* Corresponding author. Tel.: +961 1 614006; fax: +961 1 421022.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).nosocomial epidemics in intensive care and burn therapy units,
where it causes septicemia, pneumonia, and urinary tract infections
with high mortality. The treatment of infections due to A. baumannii
is a challenge because of resistance to the antimicrobial agents of
last resort, b-lactams.1 Resistance to this class of antibiotics in
A. baumannii results mainly from the production of b-lactamases,
and also from other non-enzymatic pathways, like changes in outer
membrane proteins or over-expression of efﬂux pumps.1,2 All A, B, C,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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baumannii: (1) class A extended-spectrum b-lactamases (ESBLs), (2)
class B metallo-b-lactamases, (3) class C Acinetobacter-derived
cephalosporinases (ADCs), and (4) carbapenem-hydrolyzing class D
b-lactamases (CHDLs).
Resistance to extended-spectrum cephalosporins is mainly
attributed to the over-production of chromosomal ADCs or, less
frequently, to the acquisition of an ESBL (PER, VEB, GES).3–6
Resistance to carbapenems is mainly due to transferable class D
oxacillinases of subfamilies OXA-23, OXA-24/33/40, OXA-58, and
OXA-143, or to over-production of the intrinsic OXA-51-like
enzymes.7 Some carbapenem-resistant A. baumannii expressing
class B enzymes (IMP, VIM, SIM, SPM, GIM, and NDM) and, more
recently, acquired GES and KPC carbapenemases of class A, have
been reported.8–10 Among the GES carbapenemases, GES-11 was
the ﬁrst described conferring reduced susceptibility to carbape-
nems and initially detected in A. baumannii.8 The presence of
insertion sequence ISAba1 upstream from blaOXA-23, blaOXA-58,
blaOXA-51, and blaADC provides an efﬁcient promoter for the
expression of these genes, leading to higher b-lactam hydrolysis
rates.11–14
While carbapenem resistance due to the production of CHDLs is
the most widespread in A. baumannii, Ambler class B enzymes have
been associated with carbapenem resistance in A. baumannii in
several countries, including Italy, Portugal, Japan, and Brazil.2,15 In
addition, A. baumannii acquiring GES carbapenemases have been
described in France,8 Belgium,16 and Turkey.4 In Lebanon, in 2008,
Zarrilli et al. reported a plasmid-borne blaOXA-58 gene in A.
baumannii strains selected in a Lebanese hospital.17 Lately, in
2012, NDM-1-harboring A. baumannii strains were isolated in
another Lebanese hospital from Syrian patients injured during the
civil war.18 However, no countrywide epidemiological survey has
addressed the prevalence of carbapenem-resistant A. baumannii in
Lebanon until now.
The aims of the current study were to evaluate the occurrence of
carbapenem-resistant A. baumannii in nine Lebanese medical
centers, and to describe the types of b-lactamases involved in such
resistance, as well as to investigate clonal relatedness of
incriminated strains.
2. Materials and methods
2.1. Bacterial strains
From January 1 to December 31, 2012, imipenem-resistant
isolates of A. baumannii were collected from nine Lebanese
hospitals located in diverse geographic areas: Beirut (Hotel Dieu
de France, Saint-George Hospital), Mount Lebanon (Bellevue
Medical Center), North Lebanon (Mounla Hospital), South Lebanon
(Secours Populaire Libanais Hospital, Labib Medical Center), and
Bekaa (Bekaa Hospital, Farhat Hospital, Chtaura Hospital). Selec-
tion criteria for strains were based upon the recommendations of
the Clinical and Laboratory and Standards Institute (CLSI);19 strains
with an inhibition zone diameter of imipenem 13 mm were
included and these were delivered to the central microbiology
laboratory at the Faculty of Pharmacy, Saint-Joseph University,
Beirut. The isolates were re-identiﬁed using the API 20 NE system
(BioMe´rieux, Marcy l’Etoile, France) and conﬁrmed using PCR to
detect the intrinsic blaOXA-51-like gene.
20
2.2. In vitro susceptibility testing
Antimicrobial susceptibility testing was performed by disk
diffusion on Mueller–Hinton agar using amoxicillin/clavulanic acid
(AUG), ceftazidime (CAZ), cefotaxime (CTX), cefepime (CPM), andimipenem (IMI) disks (Mast Diagnostics, Merseyside, UK), in
accordance with the recommendations of the CLSI.19
2.3. Cloxacillin test and metallo-b-lactamase detection
Antibiotic susceptibility testing was also performed using
Mueller–Hinton agar with cloxacillin (200 mg/l) to inhibit intrinsic
ADCs. An increase in inhibition zone diameters of cephalosporins
in the presence of cloxacillin was a qualitative indicator of ADC
hyper-production. Also, the cloxacillin test was used to allow
better detection of synergy between clavulanic acid and imipenem,
indicating the production of an ESBL with carbapenem-hydrolyz-
ing activity. Metallo-b-lactamases were screened for using the
combined imipenem/imipenem+EDTA Etest (Lioﬁlchem, Roseto
degli Abruzzi, Italy). A ratio of the minimum inhibitory concentra-
tion of imipenem compared to that of imipenem in the presence of
EDTA (MICimipenem/MICimipenem+EDTA) of 8 was considered a
presumptive diagnosis of metallo-b-lactamase.21
2.4. Identiﬁcation of carbapenem resistance genes
PCR sequencing experiments were used to detect carbapene-
mase genes blaoxa-23, blaoxa-24, blaoxa-40, blaoxa-58, blaKPC, blaGES,
blaIMP-1, blaIMP-2, blaNDM, and blaVIM.
22 Isolates were also screened
for insertion sequence ISAba1.14 PCR mapping using ISAba1
forward and OXA-23 reverse primers was done on blaoxa-23-
positive isolates. Also, ISAba1 forward and blaADC reverse primers
were used to locate the position of ISAba1 relative to blaADC.
2.5. ERIC-PCR
The genetic relationship between the isolates was determined
using enterobacterial repetitive intergenic consensus PCR (ERIC-
PCR), as described by Ferreira et al.23 The ampliﬁcation conditions
were as follows: an initial denaturation cycle at 95 8C for 7 min,
35 cycles at 95 8C for 1 min, 51 8C for 1 min, and 72 8C for 1 min and
30 s, and a ﬁnal extension at 72 8C for 15 min. The ampliﬁed
products were visualized on 1.5% agarose gel stained with 0.5 mg/
ml of ethidium bromide. The banding patterns were converted by
GelQuest/Sequentix software (Klein Raden, Germany) into a binary
matrix, calculated using the Dice coefﬁcient. A dendrogram was
constructed via the unweighted pair-group method using arith-
metic averages (UPGMAs). Only visible bands in the ERIC-PCR
ﬁngerprinting were used to construct the similarity matrix and the
dendrogram. Isolates with more than 85% similarity were
considered to be clonally related.
3. Results
Out of 723 A. baumannii isolated in 2012, 638 (88%) were
imipenem-resistant. Of these, 142 non-duplicate imipenem-
resistant A. baumannii isolates were received by the laboratory
for analysis. These isolates were distributed as follows: 63 were
from Saint-Georges Hospital, 36 from Labib Medical Center,
22 from Hotel Dieu de France, ﬁve from Bellevue Medical Center,
ﬁve from Bekaa Hospital, ﬁve from Chtaura Hospital, four from
Farhat Hospital, one from Mounla Hospital, and one from Secours
Populaire Libanais Hospital.
3.1. Antimicrobial resistance pattern, cloxacillin effect, and EDTA
synergy
All 142 isolates showed high resistance to the tested b-lactams
(Table 1). Sixty-eight isolates yielded a positive cloxacillin test,
indicating ADC hyper-production. Sixty-one showed synergy
between clavulanic acid and imipenem, indicating the production
Table 1
Classiﬁcation of studied imipenem-resistant Acinetobacter baumannii into seven groups based upon phenotypic and genotypic proﬁles
Group Isolate characteristics Number (%)
of strains
Number of
strains showing
IMI–AUG synergya
Inhibition zone diameters (mm)b
AUG CTX CPM CAZ IMI
1 OXA-23 + GES-11+ hyper-produced ADC 124 (87) 57 6 6 6–9 (10–14) 6–10 (6–15) 6–12
2 OXA-23 7 (5) 0 6 6 14 6 13
3 OXA-23 + GES-11 4 (3) 2 6 6 6–10 6–8 10–13
4 OXA-23+ hyper-produced ADC 4 (3) 0 14 8 (15) 20 (30) 23 (30) 6
5 OXA-24 + GES-11 1 (0.7) 1 6 6 11 6 12
6 OXA-24+ hyper-produced ADC 1 (0.7) 0 6 6 13 (16) 6 9
7 GES-11+ hyper-produced ADC 1 (0.7) 1 6 6 9 (12) 6 10
ADC, Acinetobacter-derived cephalosporinases; AUG, amoxicillin/clavulanic acid; CAZ, ceftazidime; CPM, cefepime; CTX, cefotaxime; IMI, imipenem.
a IMI–AUG synergy = synergy between amoxicillin/clavulanic acid disk and imipenem disk.
b Inhibition zone diameters between brackets are those increased in the presence of cloxacillin 200 mg/l.
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lactamase detection strips were negative for all isolates.
3.2. Molecular analysis
Genotyping allowed the detection of blaADC and bla-OXA-51
genes. GES-type carbapenemase concomitant with OXA-23 en-
zyme was observed in the majority of the isolates (128 isolates,
90%), indicating that these two carbapenemases are the most
prevalent mechanisms of resistance among our strains. Sequencing
of the blaGES variant revealed GES-11. Eleven strains harbored
either OXA-23 or OXA-24 alone, or OXA-24 with GES-11. In one
strain, GES-11 was the only detected enzyme with carbapene-
mase-hydrolyzing capacity. Tested metallo-b-lactamase-encoding
genes were not detectable in any of the isolates.
Insertion sequence ISAba1 was identiﬁed in all isolates
regardless of the type of carbapenem-hydrolyzing enzyme.
Mapping of this element in OXA-23-producers revealed a band
of size 1371 bp, indicating that ISAba1 lay upstream and adjacent
to blaOXA-23 in all strains. Mapping of ISAba1 to blaADC revealed a
band with size of 693 bp, showing that IsAba1 existed upstream
and adjacent to ADC in 97% of the isolates.
Phenotypic results combined with detected carbapenemases
were used to classify isolates into seven groups, shown in Table 1 in
decreasing frequency of detection.
3.3. Results of ERIC-PCR
Fingerprinting by ERIC-PCR showed the existence of 18 pulso-
types of imipenem-resistant A. baumannii (Figure 1). Eighty-seven
strains belonged to pulsotype 17 and originated from seven out of
nine hospitals. A smaller portion of 25 isolates belonged to
pulsotype 16 and were disseminated among seven hospitals. The
remaining strains showed various ﬁngerprinting patterns, with
fewer than 10 strains in each pulsotype, indicating different clones.
Strains from Saint-George Hospital showed the widest genotypic
variation, with 13 out of the 18 pulsotypes. Interestingly, the single
strain obtained from Secours Populaire Libanais Hospital was a
unique pulsotype (pulsotype 7). In pulsotypes 1, 16, and 17,
different carbapenemase content was noticeable among the
related isolates. For instance, strains harboring blaOXA-23 or
blaGES-11 alone belonged to pulsotype 17 together with those co-
harboring blaOXA-23 and blaGES-11.
4. Discussion
Resistance to carbapenems makes A. baumannii a challenging
pathogen to cure due to signiﬁcant compromise of treatment
options.1 In Lebanon, imipenem-resistant A. baumannii has beendescribed in two reports related to isolated Lebanese healthcare
centers,17,18 however no epidemiological countywide evaluation
has investigated the current status of carbapenem resistance in
this species. This study was conducted in nine Lebanese centers all
over the country in order to gain a wide overview of the status of
imipenem-resistant A. baumannii over a 1-year period. The
prevalence of imipenem resistance among A. baumannii in
2012 was 88%. This number is close to reported rates of 70% in
Egypt,24 72% in Turkey,25 75% in Spain,26 and up to 100% in Italy.27
The accumulation of diverse intrinsic and acquired antimicro-
bial resistance mechanisms to carbapenem accounts for these high
rates of imipenem resistance in A. baumannii worldwide. The most
prevalent mechanism of carbapenem resistance in A. baumannii is
the enzymatic degradation by carbapenemases. In this study, we
showed the presence of blaOXA-23 and blaGES-11 in the majority
(90%) of A. baumannii, conﬁrming the predominance of these genes
among Lebanese isolates. The dissemination of OXA-23 in Lebanon
is consistent with the worldwide epidemiology of OXA-2315 and
with reports from neighboring countries including Egypt,24 Iraq,28
Iran,29 and the United Arab Emirates.30 However, the co-existence
of both OXA-type and GES-type carbapenemases in A. baumannii is
not frequent, although previously reported in Kuwait31 and recently
in Tunisia.32 In addition, another OXA family, OXA-24 (groups 5 and
6), was found in Lebanon, a carbapenemase that has been described
in A. baumannii from close countries like Turkey, where it was
responsible for a hospital outbreak in an intensive care ward.33 The
OXA-58 oxacillinase, previously reported in a Lebanese hospital,17
was not detected among our isolates. This agrees with reports of a
progressive change from blaOXA-58 to blaOXA-23 carriage worldwide.
34
In addition, a recent rise in metallo-b-lactamases in A. baumannii has
been observed in some European countries.34,35 However, even
though NDM-1 has been detected recently in A. baumannii isolated
from Syrian patients hospitalized in Lebanon,18 this metallo-b-
lactamase has apparently not spread to Lebanese patients according
to the present ﬁndings.
Phenotypically, the presence of GES-11 independently from
OXA-type carbapenemases did confer cephalosporin resistance as
well as imipenem hydrolysis, like in the single isolate of group 7. In
the absence of GES-11, as in groups 4 and 6, the inhibition zone
diameters of cephalosporins were relatively higher than in group 7,
while hydrolysis of imipenem was maintained. This corresponds to
the properties of OXA-23, which exhibits mostly imipenem-
hydrolyzing activity and does not act on extended-spectrum
cephalosporins. Of note, only 62 out of the 130 GES-11-positive
isolates did yield a positive synergy test between imipenem and
clavulanic acid, indicating the pivotal role of molecular methods
for the detection of GES-producing isolates.
In addition to the acquired carbapenemases, intrinsic ADCs play
a major role in resistance of A. baumannii to b-lactams. In this
Figure 1. Dendrogram showing the genetic relationship of Acinetobacter baumannii by ERIC-PCR ﬁngerprinting, with corresponding number of strains, genotypes, and hospital
sources for each pulsotype.
A = Bellevue Medical Center, B = Bekaa Hospital, C = Chtaura Hospital, F = Farhat Hospital, HDF = Hotel Dieu de France, L = Labib Medical Center, M = Mounla Hospital, N =
number of strains, P = pulsotype, SG = Saint-George Hospital, SPL = Secours Populaire Libanais.
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production reﬂected the multifactorial aspects of b-lactam
resistance in A. baumannii. Groups 1, 4, 6, and 7 of the studied
isolates (92%) showed phenotypic evidence of hyper-produced
ADCs. In genotypic screening, 97% of the isolates revealed the
presence of ISAba1 upstream from blaADC. A comparison of groups
1 and 3, which differ only in the extent of blaADC expression,
showed that A. baumannii resistance to extended-spectrum
cephalosporins can be due to over-expression of the resident
ADCs, possibly with concomitant production of ESBLs.36
Insertion sequence ISAba1 was also adjacent to blaOXA-23. The
importance of this genetic element for carbapenem resistance in A.
baumannii has been reported, where ISAba1 exists most commonly
in association with blaOXA-23, blaOXA-58, blaOXA-51-like, and blaADC,
and constitutes a strong promoter for increased expression of the
downstream gene.1,24 In a previous study, intrinsic OXA-51
expression was reported to be increased by eight times following
insertion of ISAba1.14
ERIC-PCR, a method for rapid genetic ﬁngerprinting, was
applied to study clonal relationships between our isolates.
Eighteen different clones of A. baumannii were identiﬁed that
could not be correlated according to their phenotype or hospital
source. Pulsotype 17 was predominant in various hospitals,
indicating clonal diffusion, which may be dependent on the
permanence of A. baumannii for long periods in the hospital
environment and the transfer of patients among hospitals, which is
a common practice in Lebanon. Nevertheless, the variability in
pulsotypes also indicated probable horizontal transmission of
resistance determinants among isolates from different sources.
The results of our ﬁngerprinting analysis revealed that strains with
blaOXA-23 alone or blaGES-11 alone exhibited clonal relatedness to
those co-harboring the two genes, as in pulsotypes 1 and 17. This
may raise the possibility that these genes may be part of different
mobile elements. It was not possible in this study to perform
multilocus sequence typing (MLST). It would have been interesting
to determine if the OXA-23 and GES-11 international clones are
present in Lebanon.
In conclusion, we report the status of imipenem-resistant A.
baumannii in Lebanon with the preponderance of OXA-23 and GES-
11. Not only does this study represent the ﬁrst countrywide
assessment of carbapenem resistance in this organism, but it is also
the ﬁrst report of OXA-23, OXA-24, and GES-11 carbapenemases in
Lebanon. These resistance traits appear to spread successfully via
both bacterial epidemics and horizontal transfer. Given the
versatile and adaptable genetic background of A. baumannii and
the current population displacement and patient transfer due to
civil wars in the region, carbapenem-resistant A. baumannii strains
are expected to escalate. Continuous surveillance involving
Lebanon and neighboring countries is, therefore, crucial to limit
their propagation.
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